Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched ...
Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Nov 5 (Reuters) - Pfizer (PFE.N), opens new tab is preparing to sweeten its offer again for Metsera (MTSR.O), opens new tab, the Wall Street Journal reported on Wednesday, citing people familiar with ...